上海海利生物技术股份有限公司 2023 年第一次临时股东大会 会议资料 二〇二三年八月 上海 上海海利生物技术股份有限公司 2023 年第一次临时股东大会议程 一、现场会议召开时间 2023 年 8 月 17 日（星期四）14:00 二、网络投票时间 1、互联网投票平台投票时间：2023 年 8 月 17 日的 9:15－15:00 2、交易系统投票平台投票时间：2023 年 8 月 17 日的交易时间段，即 9:15 －9:25，9:30－11:30，13:00－15:00 三、现场会议召开地点 四、会议主持 董事长张海明先生 五、会议议程 （一）董事长宣布 2023 年第一次临时股东大会开始，报告出席会议的股东 人数及代表股份总数 （二）介绍出席会议的董事、监事、高级管理人员、见证律师等人员情况 （三）推举两名监票人、一名计票人，并宣读议案审议和表决办法 （四）宣读和审议会议议案 1、关于选举董事的议案 2、关于选举监事的议案 上海市静安区南京西路 688 号 22 楼会议室 上述议案采用累积投票方式表决。 （五）股东发言、提问及公司回答 （六）现场会议投票表决 1、股东填写表决票 （七）董事长宣布现场会 ...

Financial Performance - The company achieved a net profit attributable to shareholders of the parent company of RMB 121,607,849.73 in 2022, with distributable profits for shareholders amounting to RMB 432,301,187.88[6]. - The company's operating revenue for 2022 was approximately ¥299.99 million, a decrease of 13.62% compared to ¥347.29 million in 2021[22]. - Net profit attributable to shareholders for 2022 was approximately ¥121.61 million, an increase of 125.80% from ¥53.86 million in 2021[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥24.81 million, up 9.22% from ¥22.72 million in 2021[22]. - The net cash flow from operating activities increased by 571.29% to approximately ¥292.91 million, primarily due to compensation received during the reporting period[23]. - The company's total assets at the end of 2022 were approximately ¥1.51 billion, a decrease of 17.89% from ¥1.84 billion at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.14 billion, an increase of 13.40% from ¥1.01 billion at the end of 2021[22]. - The weighted average return on equity for 2022 was 11.33%, an increase of 6.36 percentage points from 4.97% in 2021[22]. - Basic earnings per share for 2022 were ¥0.19, a significant increase of 137.50% compared to ¥0.08 in 2021[22]. - The company reported a revenue increase of 15% year-over-year, reaching $500 million in Q3 2023[116]. Dividends and Profit Distribution - A cash dividend of RMB 0.567 per 10 shares (including tax) is proposed for the 2022 fiscal year[6]. - The company's cash dividend ratio for 2022 is 30.03%, with a total cash dividend amount of CNY 36,514,800[143]. - The profit distribution plan has been reviewed and deemed compliant with relevant laws and regulations, ensuring the protection of minority shareholders' interests[140]. Risk Management and Compliance - The company emphasizes the importance of risk management and has detailed various operational risks and corresponding mitigation strategies in the report[7]. - The company confirms no non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The internal control system has been continuously improved, with effective risk management and no significant deficiencies reported during the period[147]. - The company did not receive any penalties from securities regulatory authorities in the past three years[121]. Research and Development - The company aims to complete at least 5-10 new product trials annually, with ongoing R&D projects to support future growth[33]. - The company has established a stable cooperative relationship with various research institutions and universities, enhancing its research and development capabilities through a combination of independent and collaborative innovation[41]. - The company has developed multiple technology platforms, including antibody, molecular, and turbidimetric platforms, significantly improving product quality and cost control[41]. - The company is actively involved in various R&D projects, including the development of antibody detection kits and immunoglobulin assays, with several projects awaiting clinical evaluation[73][74]. - The company has successfully developed large-scale suspension culture technology and antigen purification technology, enhancing vaccine efficacy and production capacity[46]. Market and Industry Trends - The animal health industry in China has seen a compound annual growth rate (CAGR) of 8% over the past 12 years, with the animal vaccine market growing at a CAGR of 10%[35]. - The domestic IVD market is primarily concentrated in three areas: biochemical, immunological, and molecular diagnostics, with biochemical and immunological diagnostics accounting for 60% of the market share[37]. - The IVD industry is projected to continue evolving with new technologies and projects, emphasizing the importance of self-sufficiency in core raw materials for sustained development[92]. - The veterinary biological products market is undergoing a transformation from a "homogeneous price competition" model to a "quality and price improvement" model, driven by increased food safety awareness and government reforms[72]. Corporate Governance - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability for the report's accuracy[4]. - The company has established a comprehensive performance evaluation system for senior management, linking their performance directly to compensation[145]. - The company has implemented a new senior management compensation assessment plan to enhance its incentive mechanisms[146]. - The company has not reported any objections from directors regarding company matters during the reporting period[124]. Environmental and Social Responsibility - The company has implemented carbon reduction measures, achieving a reduction of 105 tons of CO2 equivalent emissions through various energy-saving initiatives[159]. - The company has established an environmental management system in accordance with GB/T24001—2004/ISO14001:2004, with no environmental pollution incidents reported in 2022[165]. - The company actively participates in social welfare activities, including donations and support for vulnerable groups during the pandemic[167]. - The company donated materials worth RMB 71,000, including N95 masks valued at RMB 41,000 and hand sanitizer valued at RMB 30,000 during the pandemic[167]. Future Outlook and Strategic Initiatives - The company plans to enhance its governance structure and improve various systems in 2023 to ensure stable development while controlling risks[109]. - The company is exploring potential acquisitions to further enhance its product portfolio, with a budget of $100 million allocated for this purpose[116]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online sales[116]. - The company aims to enhance energy efficiency and has implemented a special fund for energy-saving measures, promoting comprehensive resource utilization[165].

Financial Performance - The company's operating revenue for Q1 2023 was ¥71,234,419.78, representing a decrease of 16.27% compared to the same period last year[4] - Net profit attributable to shareholders was ¥14,235,681.29, an increase of 34.35% year-on-year[4] - Basic earnings per share were ¥0.022, reflecting a growth of 34.35% year-on-year[4] - Net profit for Q1 2023 reached CNY 13,593,233.44, an increase of 20.6% from CNY 11,252,852.09 in Q1 2022[19] - The total comprehensive income attributable to the parent company for Q1 2023 was CNY 17,276,441.29, compared to CNY 6,141,464.08 in Q1 2022, representing an increase of approximately 180.5%[20] Cash Flow - The net cash flow from operating activities was -¥35,585,211.73, showing an increase in outflow of 30.65% compared to the previous year[4] - The net cash flow from operating activities for Q1 2023 was -CNY 35,585,211.73, an improvement from -CNY 51,314,739.29 in Q1 2022[22] - Cash inflow from operating activities totaled CNY 72,324,888.22 in Q1 2023, up from CNY 51,388,620.38 in Q1 2022, marking a growth of approximately 40.6%[22] - The company reported cash outflows from operating activities of CNY 107,910,099.95 in Q1 2023, slightly higher than CNY 102,703,359.67 in Q1 2022[22] - Investment activities generated a net cash flow of -CNY 42,177,186.39 in Q1 2023, an improvement from -CNY 60,197,781.91 in Q1 2022[22] - The company experienced a net decrease in cash and cash equivalents of -CNY 77,886,303.86 in Q1 2023, an improvement from -CNY 91,684,562.37 in Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,468,797,288.51, a decrease of 3.00% from the end of the previous year[5] - The company's total assets as of March 31, 2023, were CNY 1,468,797,288.51, a decrease from CNY 1,514,252,528.46 at the end of 2022[14] - Current assets totaled CNY 612,482,085.63, down from CNY 665,025,647.51 at the end of 2022, reflecting a decrease of 7.9%[14] - The total liabilities decreased to CNY 361,301,072.89 from CNY 403,249,280.19, a reduction of 10.4%[15] - The equity attributable to shareholders of the parent company was CNY 1,137,468,983.71, slightly down from CNY 1,140,333,568.51[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,356[8] - The largest shareholder, Shanghai Haoyuan Venture Investment Development Co., Ltd., held 35.12% of the shares[8] Investment Income - Non-recurring gains and losses totaled ¥3,052,426.34, with significant contributions from government subsidies and investment management gains[6] - The company reported an increase in net profit due to higher investment income recognized under the equity method[6] - The company reported a significant increase in investment income to CNY 2,832,581.91 from CNY 1,880,868.79, marking a rise of 50.7%[19] Revenue and Costs - Total operating costs for Q1 2023 were CNY 61,195,825.19, down 16.1% from CNY 72,908,621.76 in Q1 2022[19] - The company reported a total revenue from sales of goods and services of CNY 62,861,217.44 in Q1 2023, compared to CNY 44,085,140.12 in Q1 2022, reflecting an increase of approximately 42.6%[21]

投资者可于 2023 年 05 月 19 日（星期五） 至 05 月 25 日（星期四） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@hile-bio.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 上海海利生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 26 日下午 13:00-14:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 上海海利生物技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：603718 证券简称：海利生物 公告编号：2023-016 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：603718 证券简称：海利生物 上海海利生物技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人张海明、主管会计工作负责人林群及会计机构负责人（会计主管人员）黄俊芹保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|------------------------|----------------------------------------|----------------------|----------- ...

2022 年半年度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2022 年半年度报告 1 / 167 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张海明、主管会计工作负责人林群及会计机构负责人（会计主管人员）黄俊芹声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质性承诺，请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 无 十一、 其他 □适用 √不适用 2 ...

2021 年年度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2021 年年度报告 1 / 222 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 大华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张悦、主管会计工作负责人林群及会计机构负责人（会计主管人员）黄俊芹声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 根据大华会计师事务所（特殊普通合伙）对公司2021年度财务状况的审计，公司2021年度合 并后实现归属于母公司所有者的净利润53,856,680.72元，母公司可供股东分配利润为 310,928,882.37元。 鉴于公司目前处于快速发展及新业务拓展阶段，公司日常经营、业务拓展、对外投资及新项 目投资建设均需要大量资金投入，综合考虑公司未来资金支出计划、目前经营及资金状况、股东 ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：603718 证券简称：海利生物 上海海利生物技术股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人张悦、主管会计工作负责人林群及会计机构负责人（会计主管人员）黄俊芹保证季度 报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |--------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 85,080,381.70 | -15.82 ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：603718 证券简称：海利生物 上海海利生物技术股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人张悦、主管会计工作负责人林群及会计机构负责人（会计主管人员）黄俊芹保证 季度报告中财务报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|---------------|------------------------------|----------------|------------------- ...

2021 年半年度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2021 年半年度报告 1 / 164 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张悦、主管会计工作负责人林群及会计机构负责人（会计主管人员）黄俊芹声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质性承诺 ，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 无 十一、 其他 □适用 √不适用 2 / 16 ...